Eli Lilly and Co. said the company’s rheumatoid arthritis drug baricitinib shortened the recovery time for hospitalized Covid-19 patients also given Gilead Sciences Inc.’s antiviral remdesivir.

French drugmaker Sanofi and Britain’s GlaxoSmithKline started a clinical trial of their protein-based Covid-19 vaccine candidate, with the companies aiming to reach the final testing stage by December.

A recent report in the New England Journal of Medicine reveals that the racial and ethnic minority groups most negatively impacted by Covid-19 are also the least represented in these clinical studies to develop vaccines and therapeutics aimed at the disease.

Roche’s attempt to retool the company’s rheumatoid arthritis drug Actemra/RoActemra to treat patients hospitalized with severe Covid-19-related pneumonia failed in a late-stage trial.

U.S. Food and Drug Administration PDUFA dates on the calendar for July include an NDA review for Jazz Pharmaceuticals’ experimental medicine for cataplexy.

Regeneron Pharmaceuticals and Sanofi said their rheumatoid arthritis drug Kevzara failed to meet the main goals of a U.S. study testing the medicine in the most critically ill COVID-19 patients.

A federal appeals court upheld two patents for Amgen’s multibillion-dollar rheumatoid arthritis drug Enbrel, rejecting Novartis’ effort to void the patents.

Eli Lilly will assess the company’s JAK1/JAK2 inhibitor Olumiant (baricitinib) as a potential treatment for COVID-19 in a Phase III study.

Exclusive: Lilly COVID-19 treatment could be authorized for use as soon as September – chief scientist (Reuters) – Eli Lilly and Co could have a drug specifically designed to treat COVID-19 authorized for use as early as September if all goes well with either of two antibody therapies it is testing, its chief scientist told […]

Roche and Gilead Sciences launched a Phase III clinical trial in severe COVID-19 pneumonia, testing Roche’s Actemra/RoActemra with Gilead’s remdesivir.